שולי רווח נקי ממכירות Zhengye Bio (ZYBT)

High barriers to entry due to patents and bio-standards make the Zhengye Biotechnology (ZYBT) niche closed. The net margin per ruble of revenue confirms this advantage, with the indicator holding around -63.40. Profit stability is ensured by streamlined temperature-controlled vaccine logistics, while scaling laboratory capacities as orders grow effectively increases the overall profitability of the business.
פילוחים אנליטיים של חברת Zhengye Biotechnology

Net profit margin measures the share of final profit in total revenue, demonstrating cost management efficiency and the business's ability to generate income from each unit of production. By analyzing the net profit margin, an investor can see the impact of high R&D expenses and the cyclical volatility of the agricultural sector on the financial stability of Zhengye Biotechnology (ZYBT) amid the slow adoption of biotechnologies.